Press release

Aeneas Capital and Pyrinas Target Launch of US$120m Fund to Develop Co-Working Laboratory Ecosystems for Life Sciences Start-Ups in the United States

Sponsored by Businesswire
  • Aeneas Capital and Pyrinas, both affiliated companies to Aptorum Group
    Ltd (Nasdaq: APM), is launching its flagship fund – Pyrinas US
    Healthcare Real Estate Fund 1 SP – to acquire and develop co-working
    space and incubator facilities for the life sciences sector in the
    United States;
  • Opportunity to invest in one of the most vibrant real estate sectors
    in the U.S. that is currently not available in most of the Asia
    Pacific countries. A great geographical and asset class
    diversification of Asia Pacific real estate investment;
  • Tap into the life sciences sector that generally has one of the
    highest barriers to entry amongst different industries;
  • Experienced and unique advisory/management team in this specific
    sector with established operation track record.

Aeneas Capital Limited (“ACL”) and Pyrinas Real Estate Management
Limited (“Pyrinas”), based in Hong Kong, is launching a US$120m
innovative closed-ended property fund – Pyrinas US Healthcare Real
Estate Fund 1 SP – with a geographical focus on selected cities across
North America. Supported by the ecosystem of its affiliated company,
Aptorum Group (Nasdaq: APM), the fund’s key investment objective is to
acquire and redevelop real estate into shared laboratories and incubator
facilities for life science sector start-ups, one of the most vibrant
sectors in North America. The fund will focus its investments in
primarily four North America mandated cities (namely Cambridge, Boston,
Houston, and San Francisco in the United States and Toronto in Canada).

This press release features multimedia. View the full release here:

Existing laboratory facilities managed by Pyrinas (Photo: Business Wire)

Existing laboratory facilities managed by Pyrinas (Photo: Business Wire)

Mr. Matthew Wong, Chief Executive Officer of Pyrinas, commented,
“These cities have been selected in view of several crucial factors that
we believe are best positioned to take advantage of the robust growth in
the life science industry. The fund will focus on acquisition and
development of real estate suitable for the healthcare and life science
sector, particularly in operating laboratories with a co-working space
model. We are seeing increasingly robust demand for space by life
science companies and start-ups, who are encouraged by the rapidly
growing venture capital investment market in North America.”

The fund is targeting a launch size of up to US$120 million with a
targeted return of 15-19% per annum (Net IRR) over a period of four
years with one-year extension. Pyrinas is currently in discussions with
a number of institutional investors and collaborative partners.

Together with its affiliated company Aptorum Group Limited (Nasdaq: APM)
and Aeneas Capital, the fund also aims to nurture medical research, the
development of intellectual property, and collaboration between
scientists, researchers, investors, and industry participants; while
providing real estate solutions that foster an ecosystem for collegial
interactions among industry, investors, government and academia.

The fund is targeted for institutional and professional investors only
and subject to restrictions in certain jurisdictions.

About the Group

Pyrinas Real Estate Management Limited (”Pyrinas”), the real
estate arm of Aeneas Group and an affiliate of Aptorum Group, was
established in 2018. Pyrinas currently is managing two laboratory
facilities and one clinic facility in Hong Kong. For more information
about Pyrinas, please visit

Aeneas Group Limited, the parent company of Aeneas Capital
Limited (“ACL”), is a multi-disciplinary financial institution
with cross border capabilities and technology services. For more
information about Aeneas Group Limited, please visit

Aptorum Group Limited (Nasdaq : APM) is a
biopharmaceutical company currently developing a portfolio of
therapeutic candidates and medical devices, and is dedicated to
developing and commercializing its portfolio of technologies to tackle
unmet medical needs observed globally. For more information about
Aptorum Group Limited, please visit

Disclaimer. The information contained in this press release
should not be construed as an offer of, or a solicitation for an
investment in, securities or any other financial instrument in any